Follistatin and myostatin: protein, gene therapy, and claims
Understand follistatin’s role, the human gene-transfer research, and why it cannot validate retail “follistatin peptide” claims.
Browse compound profiles and comparison guides. Search by name or choose a molecular class to see the evidence in context.
Understand follistatin’s role, the human gene-transfer research, and why it cannot validate retail “follistatin peptide” claims.
Learn what ACE-031 is, why its Duchenne trial stopped, and what the study can and cannot establish.
Apitegromab is an antibody, not a short peptide. Read its SMA indication, activation-blocking mechanism, and current label context.
Understand bimagrumab’s receptor target and why obesity trial results must be separated from claims about strength or short peptides.
Learn where trevogrumab acts and how to interpret the dated COURAGE findings on lean mass during semaglutide treatment.
A guide to actual short-peptide research, its preclinical stage, and the gap between laboratory findings and human benefit.
Separate five intervention types before comparing myostatin research or evaluating a claim.
Compare activation inhibitors, ligand-binding approaches, and receptor-targeting agents without turning different studies into a false ranking.
A practical reading checklist for matching a compound claim to the original study, outcomes, and limitations.
No matching articles. Try another term or choose “All topics.”